Alzheimer’s Association Welcomes U.S. FDA Approval of Lecanemab

Association Renews Urgent Call for CMS to Cover FDA-Approved Alzheimer’s Treatments CHICAGO, January 6, 2023 — The Alzheimer’s Association enthusiastically welcomes today’s U.S. Food and Drug Administration (FDA) action to grant the accelerated approval of Leqembi™ (lecanemab) (Eisai/Biogen) for the treatment of patients in mild cognitive impairment (MCI) or mild dementia stage of Alzheimer’s disease and with confirmation …

Read More